We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Unrelated Single-Stranded DNA Increases Efficiency of CRISPR-Cas 9 Gene Editing

By LabMedica International staff writers
Posted on 29 Aug 2016
Print article
Image: The crystal structure of Cas9 bound to DNA (Photo courtesy of Wikimedia Commons).
Image: The crystal structure of Cas9 bound to DNA (Photo courtesy of Wikimedia Commons).
The addition of a short section of single-stranded DNA to the reaction mixture significantly enhances the efficiency of the CRISPR/Cas9 gene editing technique.

CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs. Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

In action, CRISPR-Cas9 gene editing is a competition between cutting of the target gene and the cell's DNA repair mechanism. After Cas9 slices out the target gene, the cell exactly replaces the cut DNA, which Cas9 then slices out again. This cycle of cut and repair continues until the repair enzymes make a mistake that cannot be corrected and the gene is rendered nonfunctional.

A paper published in the August 17, 2016, online edition of the journal Nature Communications described the use of a small segment of unrelated single-stranded DNA to increase the efficiency of the CRISPR/Cas 9 technique by shortening the number of cutting and repair cycles required to disable the target gene.

Investigators at the University of California, Berkeley (USA) had found that the frequency of error-prone repair tended to increase when single-stranded DNA was present in the editing reaction. Prompted by this observation, they undertook a systematic exploration of the parameters underlying DNA-mediated stimulation of error-prone repair events. To avoid confounding effects stemming from the use of plasmid or other nucleic acid-mediated delivery of Cas9, they performed editing experiments using nucleofection to directly introduce a ribonucleoprotein complex (RNP) of Cas9 complexed with sgRNA into cells.

Results revealed that the addition of non-homologous single-stranded DNA during Cas9-mediated gene targeting greatly increased the frequency of disrupting mutations in multiple human cell lines. Consequently, this dramatically increased the number of cells with homozygous gene disruptions within the edited population. Unrelated DNA appeared to drive cells towards error-prone instead of error-free repair pathways, thereby increasing the frequency of sequence disruption by 2.5 to five times during genome editing.

"It turns out that if you do something really simple - just feed cells inexpensive synthetic oligonucleotides that have no homology anywhere in the human genome - the rates of editing go up as much as five times," said senior author Dr. Jacob Corn, assistant adjunct professor of molecular and cell biology at the University of California, Berkeley. "It gives the cell a little kick to prevent normal repair from happening."

Related Links:
University of California, Berkeley


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.